CNBX (CNBX Pharmaceuticals) Total Equity: $-2.66 Mil (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CNBX Pharmaceuticals Total Equity?

CNBX Pharmaceuticals CNBX +33.33% Total Equity is $-2.66 Mil as of May. 2026. The stock has 3 warning signs investors should review.

CNBX Pharmaceuticals's total equity for the quarter that ended in May. 2026 was $-2.66 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

CNBX Pharmaceuticals Total Equity Historical Data

* Premium members only.

The historical data trend for CNBX Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CNBX Pharmaceuticals Total Equity Chart

CNBX Pharmaceuticals Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.81 -1.63 -2.02 -2.48 -2.50

CNBX Pharmaceuticals Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.54 -2.50 -2.57 -2.53 -2.66

CNBX Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

CNBX Pharmaceuticals's Total Equity for the fiscal year that ended in Aug. 2025 is calculated as

Total Equity=Total Assets(Q: Aug. 2025 )-Total Liabilities(Q: Aug. 2025 )
=0.018-2.515
=-2.50

CNBX Pharmaceuticals's Total Equity for the quarter that ended in May. 2026 is calculated as

Total Equity=Total Assets(Q: May. 2026 )-Total Liabilities(Q: May. 2026 )
=0.013-2.673
=-2.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $-2.66 Mil mean?
CNBX Pharmaceuticals (CNBX) has a Total Equity of $-2.66 Mil as of May. 2026. The total amount of equity as record on a company's balance sheet. View historical data for CNBX Pharmaceuticals and its competitors.
Is CNBX Pharmaceuticals' Total Equity too high?
CNBX Pharmaceuticals' current Total Equity is $-2.66 Mil.
How does CNBX Pharmaceuticals' Total Equity compare to SIGY and LIPO?
CNBX Pharmaceuticals' Total Equity of $-2.66 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for CNBX Pharmaceuticals and its competitors. CNBX Pharmaceuticals's current Total Equity is $-2.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CNBX Pharmaceuticals stock overvalued right now?
CNBX Pharmaceuticals (CNBX) has a current Total Equity of $-2.66 Mil. The current Total Equity is $-2.66 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For CNBX Pharmaceuticals (CNBX), the current Total Equity is $-2.66 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CNBX Pharmaceuticals Business Description

Address No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814
CNBX Pharmaceuticals Inc is a clinical-stage biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the Cannabics SR, an oral capsule developed for the treatment of patients with cancer and cancer anorexia cachexia syndrome (CACS). It also has an anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) named RCC-33.